Stunned! In the first three quarters, this pharmaceutical company invested nearly 1.5 billion in R & D, with 28 varieties exceeding 100 million

Highlights: a few days ago, China biopharmaceutical announced its results in the first three quarters of 2017, with an operating revenue of 11.447 billion yuan, a year-on-year increase of 9.5%; R & D investment of 1.469 billion yuan, accounting for 12.8% of the revenue In addition, the sales volume of 28 varieties has exceeded 100 million yuan, of which 3 have exceeded 1 billion yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> R & D investment in the first three quarters of 2016 has exceeded that of the whole year Figure 1: R & D investment of China's biopharmaceutical industry (unit: 100 million yuan) China's biopharmaceutical industry focuses on new product R & D in the fields of cardio cerebrovascular, liver disease, anti-tumor, analgesia and respiratory system In recent years, R & D investment has grown rapidly In 2016, R & D expenditure reached hkd1599 million (about RMB 1.357 billion) In the first three quarters of 2017, it exceeded that of last year, reaching RMB 1.469 billion According to the quarterly report, China biopharmaceutical Co., Ltd has newly obtained the production approval for HIV indication of tenofovir fumarate as raw material and preparation; in addition, the original drug used for the treatment of advanced non-small cell lung cancer, androtinib capsule, is waiting for production approval; 6 products, such as abitron acetate raw material plus tablet, tofacib citrate raw material plus tablet, celecoxib capsule, shagliptin tablet, etc In addition, 12 new clinical applications and 5 new clinical approvals were submitted A total of 467 products under research, including 53 drugs for cardiovascular and cerebrovascular diseases, 33 drugs for liver diseases, 199 drugs for anti-tumor, 22 drugs for respiratory system, 26 drugs for diabetes and 134 other drugs, have been approved, under clinical trial and applied for production   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> 28 over 100 million varieties, 3 over 1 billion Chinese biopharmaceutical drugs are mainly aimed at the field of liver disease and cardiovascular and cerebrovascular treatment, and are committed to the development of drugs for the treatment of tumors, analgesia, orthopedic diseases, anti infection, parenteral nutrition, respiratory diseases, anorectal diseases, diabetes and other diseases As of the first three quarters of 2017, the sales of Tianqing Ganmei (magnesium isoglycate) injection, Runzhong (entecavir) dispersible tablets and Kefen (flurbiprofen ester) injection exceeded 1 billion yuan, of which Runzhong (entecavir) dispersible tablets reached 248747 million yuan 2; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Runzhong (entecavir) dispersible tablet Figure 2: the competition pattern of entecavir at the end of public medical institutions in China in 2016 Entecavir is an oral guanine nucleoside analogue drug independently developed by Bristol Myers Squibb Since it was launched in 2005, its sales have grown rapidly in the global market, and it is one of the most effective anti hepatitis B drugs in clinical use Runzhong (entecavir) dispersible tablet is a new hepatitis B drug developed by Zhengda Tianqing, a subsidiary of China biopharmaceutical It obtained the new drug certificate and production approval in February 2010 It is the first enterprise approved to produce the preparation in China It was launched on the market in March 2010 The sales volume in the first three quarters of 2017 was 248747 million yuan, an increase of 6.2% year on year The product is a new generation of oral guanine nucleoside analogues, mainly used in the treatment of hepatitis B virus infection, which has a strong ability to inhibit virus replication, and has a very low resistance rate According to the data of minenet, in the terminals of China's urban public hospitals, county-level public hospitals, urban communities and township health centers (referred to as China's public medical institutions), the market share of Runzhong (entecavir) dispersive tablets in 2016 has approached the original manufacturer, accounting for 42.59%, ranking the second   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> Tianqing Ganmei injection Zhengda Tianqing's liver disease medication series consists of two categories of drugs: liver protection, enzyme reduction and anti hepatitis virus medication In 2005, glycyrrhizic acid was extracted and separated from Glycyrrhiza uralensis as raw material, and then Tianqing Ganmei injection, a patent drug with structure dissimilation, was put on the market In the first three quarters of this year, the sales volume of this product reached 1526.06 million yuan, an increase of 6.1% year on year In the future, we believe that the series of drugs based on licorice can ensure that Zhengda Tianqing will maintain the leading position in the market of liver protecting and enzyme reducing drugs   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> flurbiprofen injection is a non steroidal antipyretic, analgesic and anti-inflammatory drug developed by buz company in the United Kingdom, which has a strong effect and a small therapeutic dose among similar drugs The drug is mainly used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, traumatic pain and other pain It is also a drug to relieve postoperative and various cancer pain KAIFEN injection, an analgesic drug, was developed and produced by Beijing Taide, a subsidiary of China biopharmaceutical, and was launched in 2005 Its characteristic is that the lipid microspheres targeting sustained-release preparation developed according to DDS theory has unique targeting, greatly improves the analgesic effect of the product, and significantly reduces the side effects In the first three quarters of 2017, the sales reached 1117.16 million yuan, up 26.9% year on year Source: announcement of listed company